GlassScriptPhysician profile
Satnam Sandhu
NPI 1790769149
$6,105.17
in general payments reported to CMS, 2019-2025
25 companies · $706 in 2025
The $706 reported for 2025 was more than what 84% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $847 · 2020: $374 · 2021: $930 · 2022: $1,326 · 2023: $1,303 · 2024: $619 · 2025: $706.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,504 · Education: $125.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,503.65 |
| Education | $124.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,734.22 | 2019-2025 | Farxiga, Lokelma, Airsupra |
| Amgen INC. | $706.72 | 2019-2025 | Parsabiv, Krystexxa, Tavneos |
| Horizon Therapeutics Plc | $664.14 | 2019-2023 | Krystexxa |
| Bayer Healthcare Pharmaceuticals INC. | $536.88 | 2022-2025 | |
| Vifor Pharma, INC. | $300.02 | 2019-2024 | Veltassa, Korsuva |
| Otsuka America Pharmaceutical, INC. | $279.64 | 2019-2025 | Jynarque |
| Travere Therapeutics, INC. | $237.94 | 2022-2025 | |
| Mallinckrodt Hospital Products INC. | $224.99 | 2020-2023 | Acthar |
| Opko Pharmaceuticals, LLC | $193.02 | 2021-2025 | Rayaldee |
| Mallinckrodt Enterprises LLC | $165.12 | 2019 | |
| Dendreon Pharmaceuticals LLC | $143.82 | 2025 | Provenge |
| E.R. Squibb & Sons, L.L.C. | $130.00 | 2023 | Camzyos |
| Novo Nordisk INC | $125.00 | 2024 | |
| Fresenius USA Marketing, INC. | $110.81 | 2021-2025 | Velphoro |
| Incyte Corporation | $107.74 | 2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aurinia Pharma U.S., INC. | $77.00 | 2021-2023 | Lupkynis |
| Calliditas Therapeutics US INC. | $70.47 | 2025 | Tarpeyo |
| Novartis Pharmaceuticals Corporation | $64.05 | 2021-2025 | |
| Ardelyx, INC. | $62.57 | 2023-2025 | Ibsrela |
| Akebia Therapeutics INC | $51.01 | 2020-2021 | |
| Pfizer INC. | $34.86 | 2023 | |
| Alexion Pharmaceuticals, INC. | $34.39 | 2025 | Ultomiris |
| Janssen Pharmaceuticals, INC | $20.56 | 2019 | |
| Glaxosmithkline, LLC. | $15.74 | 2022 | |
| Dexcom, INC. | $14.46 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Satnam Sandhu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.